A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors
Cancer Immunol Res. 2026 May 4;14(5):715. doi: 10.1158/2326-6066.CIR-14-5-WWR. NO ABSTRACT PMID:42076931 | DOI:10.1158/2326-6066.CIR-14-5-WWR
Cancer Immunology Reserch
Cancer cell-intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis
Cancer Immunol Res. 2026 Apr 29. doi: 10.1158/2326-6066.CIR-25-1312. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) contributes to resistance against checkpoint inhibitors. However, the precise factors that shape the immune contexture of the TME remain elusive. Here, we report that Single-Stranded DNA Binding Protein 4 (SSBP4), a previously uncharacterized protein, suppresses intratumoral T-cell … Read more
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance
Cancer Immunol Res. 2026 Apr 28. doi: 10.1158/2326-6066.CIR-25-0534. Online ahead of print. ABSTRACT Loss-of-function STK11 mutations occur in 15-20% of lung adenocarcinomas (LUAD) and correlate with immunotherapy failure and worse survival. By integrating analysis of human tumor samples, a human LUAD cell line panel, and CCLE and TCGA datasets, we found that C3 production was … Read more
Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation
Cancer Immunol Res. 2026 Apr 27. doi: 10.1158/2326-6066.CIR-25-0982. Online ahead of print. ABSTRACT The combination of multikinase inhibitors with PD-1 blockade therapy has emerged as a promising strategy to overcome resistance to PD-1 blockade monotherapy across multiple cancer types, including gastric cancer (GC). Here, we report that the multikinase inhibitor lenvatinib selectively reduced the number … Read more
An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function
Cancer Immunol Res. 2026 Apr 27. doi: 10.1158/2326-6066.CIR-25-0529. Online ahead of print. ABSTRACT Engineered T cell therapies, such as chimeric antigen receptor (CAR) and T cell receptor (TCR)-based approaches, have transformed outcomes in hematological malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or … Read more
NMB+ CXCL13+ CD4+ T cells -derived neuromedin-B promotes neuropeptide S receptor 1 positive malignant cells senescence and malignancy
Cancer Immunol Res. 2026 Apr 24. doi: 10.1158/2326-6066.CIR-25-1081. Online ahead of print. ABSTRACT Colorectal cancer (CRC) with liver metastases (CRCLM) remains a clinical challenge. CXCL13 is widely recognized as a biomarker of immunotherapy response. However, the functional heterogeneity (protumor vs. antitumor) of CXCL13⁺CD4⁺ T cell subsets has long been controversial. Through integrated analysis of single-cell … Read more
Low inflammation correlates with protumor Tim4+TREM1+ resident macrophage expansion and limited monocyte-derived macrophage differentiation during peritoneal colorectal cancer
Cancer Immunol Res. 2026 Apr 23. doi: 10.1158/2326-6066.CIR-25-0388. Online ahead of print. ABSTRACT Accumulating evidence indicates that peritoneal macrophages, comprising resident peritoneal macrophages (resMØs) and monocyte-derived non-resident macrophages (moMØs), contribute to peritoneal tumor progression, by promoting tumor cell proliferation and migration, and driving immunosuppression. However, the mechanisms governing the expansion of resMØs and moMØs, as … Read more
Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot
Cancer Immunol Res. 2026 Apr 21:OF1-OF14. doi: 10.1158/2326-6066.CIR-25-1572. Online ahead of print. ABSTRACT Colorectal cancer remains a major global health burden and an area of urgent unmet medical need. Immunotherapy has shown limited success in colorectal cancer as most patients present with an immune-excluded, “cold” tumor microenvironment (TME). In this study, we report a dual-modality … Read more
A Sampling of Highlights from the Literature
Cancer Immunol Res. 2024 Nov 4;12(11):1491. doi: 10.1158/2326-6066.CIR-12-11-WWR. NO ABSTRACT PMID:42008778 | DOI:10.1158/2326-6066.CIR-12-11-WWR
A Sampling of Highlights from the Literature
Cancer Immunol Res. 2025 May 2;13(5):617. doi: 10.1158/2326-6066.CIR-13-5-WWR. NO ABSTRACT PMID:42008760 | DOI:10.1158/2326-6066.CIR-13-5-WWR